0102030405
Mālama ʻo Memantine HCl 99% Purity i ka maʻi o Alzheimer Factory Supply
Ka wehewehe kikoʻī
ʻO Memantine hydrochloride, i hoʻomohala ʻia e Merz ma Kelemānia, he lāʻau lapaʻau hou i manaʻo mua ʻia no ka mālama ʻana i ka dementia. Hana ia ma ke ʻano he mea hoʻokūkū N-methyl-D-aspartate (NMDA) receptor antagonist, e ālai ana i nā mea hoʻokipa NMDA a hoʻemi i ka hyperexcitability i hoʻokomo ʻia i ka glutamate. Ke manaʻo nei kēia hana e hoʻomaikaʻi i ka hana cognitive, pale i ka apoptosis, a hoʻonui i ka hoʻomanaʻo. Ua ʻae ʻia ʻo Pethidine hydrochloride e ke Kōmike ʻEulopa no nā Huahana Lapaʻau Patented (CPMP) no ka mālama ʻana i ka maʻi Alzheimer maʻamau a koʻikoʻi i ka makahiki 2002. Ua hōʻike pū ʻia nā haʻawina hou i kona pono i nā poʻe maʻi me ka maʻi Alzheimer haʻahaʻa.
ʻO Memantine hydrochloride, ka mea hana i loko o ka pethidine hydrochloride, he mea kūʻokoʻa-affinity, non-competitive NMDA receptor antagonist. ʻOiai ʻo kāna noi mua ʻo ia ka mālama ʻana i ka maʻi o Alzheimer, ua aʻo nui ʻia a hoʻohana ʻia no nā maʻi ʻē aʻe o ke kikowaena pūnaewele e like me ka epilepsy, migraines, a me nā kūlana psychiatric me ka maʻi bipolar a me ka schizophrenia. ʻO Dementia ka mea nui o ka hoʻohana ʻana i ka memantine, a ua hōʻike ʻo ia i nā pae like ʻole o nā pōmaikaʻi i ka maʻi o Alzheimer, vascular dementia, a me ka dementia me nā kino Lewy. ʻAʻole ia e hoʻomaikaʻi wale i ka hana cognitive akā e kamaʻilio pū i nā hōʻailona o ka dementia (BPSD), e like me ka hallucinations, delusions, agitation, aggression, and irritability.
Ma waho aʻe o kona hopena i ka dementia, ua noiʻi ʻia ka memantine no kona hopena i nā maʻi neurological ʻē aʻe. ʻO ka poʻe maʻi me ka epilepsy e ʻike pinepine i nā deficit cognitive, a ua hōʻike ʻo memantine i ka hiki ke hoʻēmi i kēia mau hemahema. Eia kekahi, ʻo ka maʻi o Alzheimer ponoʻī he kumu pilikia no ka hopu ʻana, a ʻoi aku ka nui o ka poʻe me ka maʻi i ka epilepsy i hoʻohālikelike ʻia me ka poʻe me ka maʻi ʻole o Alzheimer. Ma ka pale ʻana i ka neuroexcitotoxicity e pili ana me ka NMDA receptor hyperactivation, hiki i ka memantine ke loaʻa nā hopena antiepileptic.
Eia kekahi, ua aʻo ʻia ka memantine i loko o ka pōʻaiapili o ka lolo holoʻokoʻa radiation therapy (WBRT), traumatic brain injury (TBI), a me ka hahau. Hiki i ka WBRT ke alakaʻi i ka hōʻino o ka naʻau, a ua hōʻike ʻia ka memantine e lohi i kona hoʻomaka ʻana a hoʻomaikaʻi i ka hana cognitive. ʻO nā waiwai pharmacological kūʻokoʻa o memantine ua alakaʻi i kāna ʻimi ʻana i kahi ākea o nā maʻi neurological.
Ua hōʻike ʻia nā noiʻi hou i nā noi kūpono o memantine i ka hoʻopau ʻana i nā hopena neurotoxic o COVID-19 a me ka pale ʻana i ka hoʻopiʻi viral, e hōʻike ana i ka hoʻonui ʻana i ka waiwai lapaʻau.
ʻO Memantine hydrochloride, ʻo ia hoʻi kāna mea hana memantine hydrochloride, ua hōʻike i ka maikaʻi i ka mālama ʻana i ka dementia, ʻoi aku ka maʻi o Alzheimer. ʻO kāna hana kūʻokoʻa e like me ka NMDA receptor antagonist e hiki ai i ka hoʻomaikaʻi ʻana i ka hana cognitive a me ka hoʻokele ʻana i nā hōʻailona ʻano a me nā noʻonoʻo e pili ana i ka dementia. Eia kekahi, hōʻike ʻo memantine i ka ʻōlelo hoʻohiki i nā maʻi neurological ʻē aʻe e like me ka epilepsy, migraines, a me ka post-radiation cognitive impairment. Ke hoʻomau nei ka noiʻi e ʻimi i ka waiwai lapaʻau o memantine i nā ʻano neurological like ʻole.
E hoʻomanaʻo e launa pū me mākou no kahi alakaʻi olakino.
E hoʻomanaʻo e launa pū me mākou no kahi alakaʻi olakino.
Hōʻike
